COMMUNIQUÉS West-GlobeNewswire

Option Care Health Announces Financial Results for the Third Quarter Ended September 30, 2024

30/10/2024 - 12:00

BANNOCKBURN, Ill., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion [...]

OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference

30/10/2024 - 12:00

LONDON and NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), [...]

Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update

30/10/2024 - 12:00

TEL AVIV, Israel, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (“Chemomab” or the “Company”), a clinical stage biotechnology company developing innovative therapeutics for fibro- [...]

Telix Partners with Subtle Medical on AI-Enabled SubtlePET™ Software for Faster PET Imaging with Illuccix®

30/10/2024 - 11:33

MELBOURNE, Australia, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a partnership with California-based Subtle Medical, Inc. (Subtle Medical) for [...]

Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference

30/10/2024 - 11:14

Dose-dependent increase in neuroprotective APOE2 expression in all participants with ongoing durability at 12 months Consistent reductions across CSF tau biomarkers and tau PET in majority of participants LX1001 well [...]

Anaveon announces presentation of new data on development compounds ANV700 and ANV600 at the Society for Immunotherapy of Cancer 2024 Annual Meeting

30/10/2024 - 08:00

- First presentation of ANV700, a targeted IL-21 employing proximity activated potentiation of cytokine signaling - - New mechanistic data provide insights into the mode of action of ANV600, currently in clinical [...]

Final Results

30/10/2024 - 08:00

DXS INTERNATIONAL PLC (AQSE: DXSP) ANNUAL RESULTS for the year ended 30 April 2024 The Board of DXS International plc (“the Company” or “DXSP”), the AQSE Growth Market quoted healthcare information and digital clinical [...]

Sandoz reports third-quarter and nine-month 2024 sales

30/10/2024 - 07:00

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong third-quarter biosimilars growth of 37% in constant currencies from existing portfolio and recent launches Generics growth [...]

Avance Clinical CEO and Asia Director Sign MOUs with Key Clinical Trial Sites in Korea around 2024 KoNECT

30/10/2024 - 03:18

WAKE FOREST, N.C. and ADELAIDE, Australia , Oct. 29, 2024 (GLOBE NEWSWIRE) -- Avance Clinical , a leading full-service global Contract Research Organization (CRO) known for delivering high-quality, agile clinical [...]

EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering

30/10/2024 - 02:47

WATERTOWN, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with [...]

Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

30/10/2024 - 02:05

GAITHERSBURG, Md., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused [...]

PROCEPT BioRobotics Corporation Announces Pricing of Offering of Common Stock

30/10/2024 - 01:43

SAN JOSE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics” or the “Company”), a surgical robotics company focused on advancing patient care by developing [...]

Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock

30/10/2024 - 01:21

BRISBANE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with [...]

Enzo Biochem Reports Fourth Quarter and Fiscal Year 2024 Results and Announces Cash Dividend

30/10/2024 - 00:59

FARMINGDALE, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal fourth quarter ended July 31, 2024 and the fiscal year ended [...]

Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development

29/10/2024 - 23:39

Companies will discuss how Lantern’s AI platform is being leveraged for the identification and development of enrichment biomarkers for Actuate’s lead investigational drug product, elraglusib CHICAGO and FORT WORTH, [...]

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases

29/10/2024 - 23:00

The collaboration aims to discover and develop molecular glue degrader clinical candidates for priority targets to Biogen. Collaboration leverages Neomorph's leading molecular glue discovery platform and Biogen’s deep [...]

BioAdaptives, Inc. Letter to Shareholders Regarding the Reverse Stock Split

29/10/2024 - 22:35

LAS VEGAS, Oct. 29, 2024 (GLOBE NEWSWIRE) -- via IBN -- Due to a website maintenance error, a draft of a letter to BioAdaptives ® (OTC: BDPT) shareholders was made available on the BioAdaptives ® website. While the [...]

Privia Health Reports 2023 Performance Results in the Medicare Shared Savings Program

29/10/2024 - 22:04

$176.6 Million in Shared Savings Delivered Across 10 Participating ACOs ARLINGTON, Va., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced that its Accountable Care Organizations [...]

Harvard Bioscience Schedules Third Quarter 2024 Earnings Conference Call for November 7, 2024 at 8:00 AM ET

29/10/2024 - 22:00

HOLLISTON, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended September 30, 2024 before the market opens on November 7, 2024, and [...]